Breaking News

Unigene Regains Rights to Osteoporosis Therapy

Seeks new development partner for oral PTH program

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Unigene Laboratories and GlaxoSmithKline have amended agreements relating to exclusive worldwide license, development services, and clinical supply for an oral formulation of a recombinantly produced parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women. GSK decided not to pursue development based on its internal evaluation criteria, allowing Unigene to regain exclusive worldwide rights to the oral PTH program with no financial obligations to GSK. Ashleigh P...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters